Brief: Cosmo Pharmaceuticals: FDA Extends NDA Review Period For BYFAVO(TM)

Cosmo NV

12/03/2020 11:54

March 12 (Reuters) - COSMO PHARMACEUTICALS NV  COPN.S :
    * FDA HAS EXTENDED REVIEW PERIOD FOR NEW DRUG APPLICATION
(NDA)
FOR BYFAVO(TM) (REMIMAZOLAM) BY UP TO 90 DAYS
    * EXTENSION  IN ORDER TO COMPLETE ITS REVIEW OF ADDITIONAL
DATA
SUBMITTED IN JANUARY AND FEBRUARY 2020

Source text for Eikon:  ID:nTENb7jjta 
Further company coverage:  COPN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))